TEMPUS CAPITAL INC. Logo
CA88024G1019
A2PE0F
TEMP.CN

TEMPUS CAPITAL INC.

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • Tempus AI secures $1.1 billion in data contracts, shares rally

    Tempus AI said it signed $1.1 billion in sealed data contracts with 70 customers in 2025, including major life-sciences firms such as AstraZeneca, Pfizer, Merck and Abbvie. The company reported revenue retention around 126% and called 2025 a record year for its Data and Applications business. Shares rose as much as 15% intraday and closed up 4.51% at $69.26. Tempus AI plans to finalize and report full 2025 financial results on an earnings call in February 2026. » Mere på finance.yahoo.com


  • Tempus AI raises FY25 guidance, cites FDA clearance and Paige acquisition as growth drivers

    Tempus AI guided FY25 revenue to $1.25–$1.26 billion (about 81% YoY) and expects roughly $1.55 billion in FY26 revenue, valuing the company at ~9.16x 2026 sales. Recent catalysts include FDA clearance for its xR IVD product and the $81 million acquisition of Paige, which expand addressable markets and AI pathology capabilities. Analysts note strong revenue visibility and execution, while valuation appears supported by forward growth despite a trailing P/E around 41.5 and elevated share performance since April. » Mere på finance.yahoo.com


  • Tempus AI reaches all-time high of $98.14

    Tempus AI stock climbed to an all-time high of $98.14, bringing market capitalization to about $16.16 billion. Analyst price targets range from $60 to $100; Guggenheim raised its target to $95 and H.C. Wainwright to $98. Tempus recorded revenue growth of 59.84% over the last twelve months and a 1-year performance of +96.54%. The company received FDA 510(k) clearance for the RNA-based diagnostic Tempus xR IVD and expanded its CARE program for breast cancer screening. » Mere på de.investing.com


  • ARK Invest increases stake in AMD and divests heavily from Tempus AI

    Cathie Wood’s ARK ETFs bought 25,899 shares of Advanced Micro Devices through ARKF on September 16, worth about $4.17 million. At the same time, a total of 167,598 shares of Tempus AI were sold via ARKK and ARKG for roughly $14.27 million, part of an ongoing reallocation toward selected technology and biotech names. » Mere på de.investing.com


  • Cathie Woods' ARK ETFs sell Tempus AI and buy Arcturus

    In the trading session on September 15, 2025, Cathie Woods' ARK ETFs adjusted their portfolios: via ARKG, 7,270 shares of Tempus AI were sold for $627,982, while 27,408 shares of Arcturus were purchased for $474,706. At the same time, ARK made buys in Bullish, eToro, Figma and Toast and sales of Kratos, Rocket Lab and Shopify. The transactions point to a strategic reshuffle within the fund's biotechnology and AI positions. » Mere på de.investing.com

I 2023 har TEMPUS CAPITAL INC. allerede udloddet 0,034 € i udbytte. Den seneste udlodning fandt sted i august 2023.

Virksomhedstal

I det seneste kvartal havde TEMPUS CAPITAL INC. en omsætning på 73,2 t € og et nettoresultat på -34,56 t €
(EUR) juni 2026
YoY
Omsætning 73,2 t 2,72 %
Bruttofortjeneste 36,96 t 2,92 %
Nettoresultat -34,56 t 11,85 %
EBITDA 2,21 t 243,99 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
2,81 mio. €
Antal aktier
30,48 mio.
Højeste/laveste i 52 uger
0,0954 € - 0,0254 €
Udbytte Nej
Beta
-0,04
P/E (PE Ratio)
-17,26
PEG (PEG Ratio)
8,68
K/I (PB Ratio)
2,62
P/S (PS Ratio)
8,96

Virksomhedsprofil

Tempus Capital Inc. driver virksomhed inden for ejendomsdrift i Canada. Selskabets ejendomsportefølje omfatter fire ejendomme, bestående af et kommercielt butikscenter, én kommerciel ejendom og to blandede kommercielle/boligejendomme i Ontario. Tempus Capital Inc. blev stiftet i 2011 og har hjemsted i Burlington, Canada.

Navn
TEMPUS CAPITAL INC.
CEO
Russell Tanz
Hjemsted Burlington, on
Canada
Websted
Branche
Maskiner
Børsnotering
28.02.2019

Tickersymboler

Børs Symbol
Cnq
TEMP.CN
🍪

Parqet  bruger cookies. Læs mere